WASHINGTON -- (BUSINESS WIRE) -- Fourth bullet of release dated January 23, 2013, should read: John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences, Inc. (sted John F. Milligan, PhD, President and Chief Operating Officer, Gilead Pharmaceuticals).
The corrected release reads:
15TH ANNUAL BIO CEO & INVESTOR CONFERENCE TO FEATURE FIRESIDE CHATS BETWEEN BIOPHARMA EXECUTIVES AND ANALYSTS
Industry leaders will discuss recent company successes and their biggest fears, and what’s ahead for the industry in 2013
The Biotechnology Industry Organization (BIO) today announced this year’s Fireside Chats lineup for the 15th annual BIO CEO & Investor Conference. The chats will feature a set of moderated, one-on-one conversations with industry leaders, followed by an interactive question and answer session. The event, to be held in New York City, February 11 – 12, 2013, is the largest independent investor conference focused on publicly-traded biotechnology companies.
“The biotech industry has weathered some storms since the financial crisis, but the innovations and successes that come out of this industry continue to inspire me,” said Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin. “The BIO CEO and Investor Conference brings together high-level industry stakeholders and addresses the timeliest and most relevant issues we face. I’m pleased to represent BioMarin in such a forum.”
Last year, the FDA approved 40 novel drugs (15 being orphan drugs), an approval rate not seen in this industry since the 1990s. The top three therapeutic areas (cancer, cardiovascular, and metabolic) accounted for 60% of novel drug approvals. The 2013 Fireside Chat lineup includes CEOs from public companies with 2012 FDA approvals, including Gilead (GILD) and Onyx (ONXX) with others on track for additional filings this year. The complete list of participants in presenting order includes:
In addition to Fireside Chats, the conference will host Therapeutic Workshops, Business Roundtables and BIO One-on-One Partnering™. BIO One-on-One Partnering™ system provides the opportunity to arrange meetings between investors, companies and industry executives. Furthermore, the event features presentations from more than 130 leading biotechnology and pharmaceutical companies.
Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration. Equity research analysts from investment banking institutions also qualify as investors. Media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors. The bank sponsors include: Stifel Nicolaus Weisel, Leerink Swann and ROTH Capital Partners, LLC.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit here.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
Upcoming BIO Events
Asia International Conference
January 29 – 30, 2013
CEO & Investor Conference
February 11 – 12, 2013
New York City, NY
March 25 – 27, 2013
San Diego, CA
April 22 – 25, 2013
Congress on Industrial Biotechnology
June 16 – 19, 2013